Manal Bosseila

Manal Bosseila

Auto-generated profile, based on publicly available information

Manal Bosseila

Dermatology Department, Faculty of Medicine, Cairo University, Egypt

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Journal of Dermatological Science
Verified
Journal Article
Closed access
MEMohammad Maged. Y. El-Batawy
Mohammad Maged. Y. El-Batawy
MBManal A.-W. Bosseila
Manal A.-W. Bosseila
HMHeba M. Mashaly
Heba M. Mashaly
VHVanessa Suzan G.A. Hafez
Vanessa Suzan G.A. Hafez

14 May 2004 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Closed access
PDF file
MEM. El‐Mofty
M. El‐Mofty
WMW. Mostafa
W. Mostafa
MEM. El‐Darouty
M. El‐Darouty
MBM. Bosseila
M. Bosseila
HNH. Nada
H. Nada
GEG. El‐Enani
G. El‐Enani

1 April 2000 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Closed access
PDF file
MEM. El‐Mofty
M. El‐Mofty
HZH. Zaher
H. Zaher
MBM. Bosseila
M. Bosseila
RYR. Yousef
R. Yousef
BSB. Saad
B. Saad

24 November 2005 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Closed access
PDF file
MEM. El‐Mofty
M. El‐Mofty
MEM. El‐Darouty
M. El‐Darouty
MSM. Salonas
M. Salonas
MBM. Bosseila
M. Bosseila
SSS. Sobeih
S. Sobeih
GEG. El‐Enany
G. El‐Enany

28 July 2010 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
MEM. El-Mofty
M. El-Mofty
WMW. Z. Mostafa
W. Z. Mostafa
MBM. Bosseila
M. Bosseila
RYR. Youssef
R. Youssef
SES. Esmat
S. Esmat
MFM. Fathy
M. Fathy
Psoriasis, vitiligo, and mycosis fungoides (MF) are among the most frequently treated dermatological diseases by photo(chemo)therapy. The objectives are to determine which photo (chemo) therapeutic modality could achieve the best response in the treatment of psoriasis, vitiligo, and MF. The design used in this study is retrospective analytical study. The study included 745 patients' records; 293 with psoriasis, 309 with vitiligo, and 143 with early MF, treated in the Phototherapy Unit, Dermatology Department, Kasr El‐Aini Hospital, Cairo University by either psoralen and ultraviolet A (PUVA), narrow band ultraviolet B (NB‐UVB), psoralen and narrow band UVB (P‐NBUVB), broad band UVB (BB‐UVB), or broad band UVA (ΒΒ‐UVA). Data were retrieved from the computer database of the unit and statistically analyzed. In psoriasis, oral and topical PUVA and NB‐UVB were found to be equally effective, whereas oral PUVA had significantly better results than both UVA and BB‐UVB at the end of therapy. In generalized vitiligo, PUVA and P‐NBUVB had significantly better results than NB‐UVB alone. In early MF, there was no statistically significant difference between the response to oral PUVA and NB‐UVB. PUVA and NB‐UVB are good choices in patients with psoriasis and early stage MF, whereas PUVA appears the best choice in the treatment of vitiligo.

1 July 2014 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
VHVanessa G. Hafez
Vanessa G. Hafez
MBManal Bosseila
Manal Bosseila
MHMona R. E. Abdel Halim
Mona R. E. Abdel Halim
OSOlfat Shaker
Olfat Shaker
MKManal Kamal
Manal Kamal
HKHeba Sherif Kareem
Heba Sherif Kareem
To evaluate the therapeutic efficacy of pioglitazone on psoriasis vulgaris and its comorbidities. Forty-eight patients with moderate-to-severe psoriasis vulgaris were enrolled in this randomized double blinded placebo-controlled trial. Active treatment included: oral pioglitazone 30 mg daily for 10 weeks. Primary outcome (treatment success) was PASI-75. Secondary outcomes included changes in metabolic syndrome, insulin resistance and cardiovascular risk. Treatment success was achieved in 5/24 (21%) in the pioglitazone group compared to 1/24 (4%) in the placebo group; however, this difference was not significant (p = 0.081). Compared to placebo, no significant difference existed as regards high-sensitive C reactive protein. Metabolic syndrome and insulin resistance were not affected. This short term (10 weeks duration) study revealed no effect of pioglitazone 30 mg daily neither on the clinical response of moderate-to-severe psoriasis nor on metabolic syndrome and insulin resistance. Cardio-protective role appears to be more related to improvement of psoriasis. Short duration of treatment and small number of subgroups.